{"entity":{"id":"nkt5097","kind":"drug","name":"NKT5097","aka":[],"tldr":"NKT5097 is an experimental protein degrader from NiKang Therapeutics, in phase 1 trials for HR-positive breast cancer and CCNE1-amplified solid tumours.","summary":"NKT5097 is a small molecule degrader, oral from NiKang Therapeutics. A dual degrader of CDK2 and CDK4, cell-cycle enzymes. The phase 1 study NCT07029399 tests it alone and with fulvestrant or letrozole. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"NiKang science and pipeline","url":"https://www.nikangtx.com/science-and-pipeline/"},{"label":"ClinicalTrials.gov NCT07029399","url":"https://clinicaltrials.gov/study/NCT07029399"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":["cdk2"],"drugs":[],"companies":["nikang-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07029399"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"NKT5097","modality":"Small molecule degrader, oral","mechanism":"A dual degrader of CDK2 and CDK4, cell-cycle enzymes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/nkt5097/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/"}],"company":[{"id":"nikang-therapeutics","kind":"company","name":"NiKang Therapeutics","route":"/companies/nikang-therapeutics/"}],"trial":[{"id":"nct07029399","kind":"trial","name":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","route":"/trials/nct07029399/"}]}}